Upon treatment with KCI807, that disrupts ELK1-AR interactions but not the ERK1/2-mediated phosphorylation of ELK1, the growth of the cells declined, both in castration/enzalutamide-resistant cell lines and patient-derived tumor xenografts (Table 3) [140]. The gene discussed is ELK1; the disease is neoplasm.